Potential Sciences Leaves Stealth With UK Sovereign AI Backing to Run Quantum Chemistry on GPUs for Small-Molecule Drug Discovery, November 2026
How Potential Sciences plans to generate physics-grade chemistry data for drug discovery on GPUs
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A UK startup called Potential Sciences came out of stealth in November 2026 with an investment from Sovereign AI, the British government's venture fund for artificial intelligence companies, and a plan to generate chemistry data from first-principles physics for small-molecule drug discovery. The company says it has rebuilt quantum chemistry software to run on graphics processing units, at a reported cost 100 times lower than traditional implementations on central processors.
The quantum element in this story is the physics inside each calculation. Quantum chemistry computes how the electrons of a molecule behave, and the resulting energies indicate how strongly a candidate drug may bind to a protein or how a reaction may proceed. These calculations run on conventional processors, and the announcement makes no claim about quantum computers.
Sovereign AI says it is supporting the company with compute through the AI Research Resource, the UK's public supercomputing capacity for artificial intelligence research, so that Potential Sciences can produce "millions of highly accurate chemistry calculations for AI models to learn from". Hatem Helal is the founder and chief executive. Josephine Kant, an investment partner at Sovereign AI, is quoted alongside him. Nauta Capital, which also invested, put the round at eight figures in capital and compute combined, led by Sovereign AI and Twin Path Ventures, and gave no separate cash amount.
The Sovereign AI announcement starts from a data problem. Machine-learning models for chemistry learn from examples, experimental chemistry data is slow and expensive to produce, and many existing computational datasets rely on approximate calculations that, in the fund's words, "struggle to capture the small differences that can determine whether a drug binds to its target or a chemical reaction works as expected". More accurate methods exist, and their cost on central processors has kept them out of the dataset sizes that modern models need.
Nauta Capital's announcement of 5 November 2026 names the method: the company's engine "runs gold-standard CCSD(T) calculations at 100 times lower cost than traditional implementations", which Nauta says lets it generate data for millions of molecules where the field could previously afford thousands. Nauta also states that the compute partnership gives access to the Isambard-AI supercomputer in Bristol. CCSD(T), coupled-cluster theory with single, double and perturbative triple excitations, was introduced in 1989 by Krishnan Raghavachari, Gary Trucks, John Pople and Martin Head-Gordon, and chemists widely use it as the reference method for the energies of small molecules. Its computing cost grows roughly with the seventh power of the size of the molecular system, which is why it is usually reserved for small molecules and benchmark sets. Helal's own phrase in the announcement is "gold-standard accuracy".
The 100-fold figure needs its context. Sovereign AI describes it as "a reported 100 times lower cost than traditional CPU-based implementations", a statement about the price of one class of calculation, issued by the company and its investors. No benchmark, preprint or code release accompanies the announcement. Gizmodo Brasil, reporting on 6 November 2026, makes the same point: a calculation that costs 100 times less does not mean that developing a complete medicine becomes 100 times cheaper or faster.